NewLink Genetics (Ames, IA) a clinical-stage biopharmaceutical company focused on lung and pancreatic cancers, closed a $7.5M Series D financing. Prior investors have included Iowa Capital Group, Ames Seed Capital, Chicagoland Investors, Midwest Oilseeds and NLG Advisors.